Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PMA 1994 ADS WOULD FOCUS ON "DISCOVERY"

Executive Summary

PMA 1994 ADS WOULD FOCUS ON "DISCOVERY" of new therapeutics according to proposals being prepared for the Pharmaceutical Manufacturers Association board, PMA President Gerald Mossinghoff told a health reporters breakfast Nov. 2 in Washington, D.C. Noting that the second year of PMA's nationwide print ad campaign is "winding down," Mossinghoff said that the association staff will present the board of directors in December "ideas which are still being formulated now for a continuation of [the campaign] either in print or maybe in TV form." For the first two years, the campaign has focused on the cost effectiveness of drugs. For 1994, "the planning is it will focus on discovery," Mossinghoff said. The ads are designed to "plant the major premise, and that is that we are the discoverers of new drugs. That is not widely known," he continued. Some PMA companies, such as Glaxo, have been independently sponsoring television and print ads that focus on industry research. As with the current campaign, Mossinghoff said, the new ads will "probably not directly tie into" the health reform debate. "You do have to be very careful of your message," he said. Mossinghoff's remarks came one day after the Health Insurance Association of America received a highly publicized rebuke from Hillary Rodham Clinton for its ads questioning elements of the Administration reform plan. The budget for the current print ad campaign is $7 mil., Mossinghoff said. "It looks like the request is shaping up for about the same amount" for 1994. Eisner & Associates of Baltimore is directing the campaign. The association is in the process of surveying 1,500 "opinion leaders" to estimate the effectiveness of the campaign. A survey after the first year of the ads showed no improvement in the industry image. However, Mossinghoff suggested wrily that taken in the context of attacks on the industry by President Clinton, "maybe that's [a sign of] a very successful ad." "When the board signed on to an advertising program," Mossinghoff added, "they knew it was a long haul situation...I believe that we have [a] general board philosophical buy-in to the fact that this is for the long haul." The advertising program has been funded by special assessments on members. Mossinghoff reported that PMA's "We Care" program, which signed up member companies to enlist shareholders, retirees and employees to lobby Congress, generated "almost 200,000 messages... to either district offices or congressional offices." The "message there was very straightforward: no government price controls on pharmaceuticals."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel